Increased antitumor effect of immunoconjugates and tumor necrosis factor in vivo.
The potential of specifically targeting antineoplastic drugs and toxins to tumors with the use of monoclonal antibodies (MoAbs) reactive with tumor-associated antigens is currently being examined. N-Acetyl-melphalan-MoAb (N-AcMEL-MoAb) conjugates have previously been shown to have greater antitumor activity than N-AcMEL, melphalan, or MoAb alone against both subcutaneous and ascites murine thymomas in mice (1). Although this conjugate is also a highly selective tumor inhibitor in vitro, it may not reach all the tumor cells in a high concentration, and consequently larger tumors (greater than 0.4 cm2) cannot be eradicated. This conjugate is representative of many drug-MoAb conjugates in that they are unable to gain adequate access to the tumor site to exert their cytotoxic effect. To potentiate the antitumor effect of the N-AcMEL-MoAb conjugate, studies were undertaken to analyze its action in combination with recombinant human tumor necrosis factor alpha (rTNF-alpha), a monokine, capable of causing acute necrosis of syngeneic tumor transplants in mice. Treatment of mice with murine thymomas (0.4 to 0.6 cm2 in size) demonstrated that 30% of the tumors in mice receiving conjugate and rTNF-alpha partially or completely regressed, while no regressions were observed in the tumors of mice receiving N-AcMEL-anti-Ly-2.1 conjugate or rTNF-alpha alone. This and other experiments indicated that the antitumor effect and tumor localization of N-AcMEL-MoAb conjugates can be enhanced in vivo by rTNF-alpha, thereby enabling successful eradication of larger established subcutaneous murine tumors.
Smyth
M J
MJ
Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.
Pietersz
G A
GA
McKenzie
I F
IF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents; D007167:Immunotherapy; D000922:Immunotoxins / Q000378:metabolism / Q000627:therapeutic use*; D051379:Mice; D011994:Recombinant Proteins / Q000627:therapeutic use; D013945:Thymoma / Q000628:therapy*; D014018:Tissue Distribution; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000922:Immunotoxins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha